MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens
We find that the effective antitumor immunity targeting neoantigens in these breast cancer models is determined by MHC-II-restricted presentation of optimal cancer-associated antigens. These responses are dependent on CD4+ T cells, B cells, and antigen-specific antibodies.
Authors
- Sarah A Castro
- Michael J. Hansen (ORCID: https://orcid.org/0000-0001-7712-0375)
- James W. Jenkins (ORCID: https://orcid.org/0000-0001-5694-9707)
- S Foster (ORCID: https://orcid.org/0000-0002-9747-3853)
- Sara J. Felts (ORCID: https://orcid.org/0000-0003-3686-2617)
- Aaron J. Johnson (ORCID: https://orcid.org/0000-0002-7921-484X)
- Kevin D. Pavelko (ORCID: https://orcid.org/0000-0001-7555-1315)
- Larry R. Pease (ORCID: https://orcid.org/0000-0001-9770-1740)
- Virginia P. Van Keulen (ORCID: https://orcid.org/0000-0001-6496-1095)
- S. Olivier
- Destin T Hinson
- Alvaro Peña
- Pablo E Rios-Cruz
- Joshua Yakubov
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-010434
- Citations
- 3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 2.39